Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply

Aliment Pharmacol Ther. 2023 Dec;58(11-12):1243. doi: 10.1111/apt.17750.

Authors

Aakash Desai¹, Miguel Regueiro², Gursimran S Kochhar³

Affiliations

¹ Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
² Division of Gastroenterology & Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
³ Division of Gastroenterology & Hepatology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.

PMID: 37986600
DOI: 10.1111/apt.17750

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Colitis, Ulcerative* / drug therapy
Humans
Ustekinumab* / therapeutic use

Substances

Ustekinumab
vedolizumab
tofacitinib
Antibodies, Monoclonal, Humanized